SVRA Nov 2024 4.000 call
| Previous Close | 0.8500 |
| Open | 0.8500 |
| Bid | 0.0000 |
| Ask | 1.3000 |
| Strike | 4.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.8500 - 0.8500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 34 |
Insider MonkeyDid Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?
We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Savara Inc. (NASDAQ:SVRA) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry has been […]
Business WireSavara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
LANGHORNE, Pa., June 28, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, for total gross proceeds of approximately $100.0 million. All of the securities to be sold in the offering are being sold by Savara. The offering included the following investo
Business WireSavara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa., June 26, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, Phase 3 IMPALA-2 clinical trial. IMPALA-2 is a 48-week, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of molgramostim 300 mcg administered once daily by inhalation with matching placebo in adult patients with aPAP (NCT04544293). Molgramostim is an inhaled
